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Abstract: In last decades, Transient Receptor Potential Vanilloid 1 
(TRPV1) has been the target of a large number of scientific investigations. 
It has been identified as a polymodal transducer molecule on a sub-set of 
primary sensory neurons which responds to various endogenous and 
exogenous stimuli including noxious heat (more than 42°C), protons and 
vanilloids such as capsaicin, the hot ingredient of chilli peppers. In 
mammals, TRPV1 displays a wide tissue and cellular expression including 
both the peripheral and central nervous system, with broad distribution and 
functions, in physiological and pathological conditions. Its primary 
localisation in sensory neurons reveals its key nodal point in pain 
transmission pathways. Nowadays, it is clear that TRPV1 is involved in 
inflammation, pain perception and thermoregulation in the majority of 
animals, including humans. Recently, a lot of studies tried to investigate 
some analgesic treatments applied on TRPV1. The aim of this review is to 
give to the readers a short overview of the TRPV1 involvement in pain 
perception and possible therapeutic applications, highlighting this topic in 
species of interest in veterinary medicine. 
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Introduction 
All animals evolved a specific behaviour to prevent 
injury when exposed to physical and chemical stimuli 
(Kuffler et al., 2002). Vertebrates and invertebrates have 
an accurate and efficient perception of environmental 
stimuli in order to survive. Sensory neurons are able to 
detect these stimuli through receptors present in the 
peripheral nervous system and that can transduce 
information to the Central Nervous System (CNS). 
Among these, it is possible to find Transient Receptor 
Potential Vanilloid 1 (TRPV1), one of the most 
extensively studied member of the TRP family of ion 
channels (Montell, 2005). 
TRPV1 is a non-selective cation channel that has a 
high permeability to Ca
2+
 and its activation induces 
sensory nerve endings depolarization and evokes a 
series of responses that propagates from the spinal cord 
to the brain (Premkumar et al., 2002; De Petrocellis and 
Moriello, 2013). It contributes to the detection of 
noxious thermal stimuli by primary sensory neurons of 
the pain pathway (Tominaga et al., 1998; Caterina and 
Julius, 2001). Electrophysiological and genetic studies 
demonstrated that TRPV1 is activated by heat (more 
than 42°C), acid pH, specific ligands (i.e.: Capsaicin) 
and by a number of chemical factors produced during 
inflammation (i.e., Diacyl-glycerol-DAG-, 
phosphatidylinositol 4,5-biphosphate-PIP2-, anandamide 
and other negatively charged lipids) that can directly 
potentiate the effects of capsaicin or heat (Tominaga et al., 
1998; Jordt et al., 2000; Sprague et al., 2001; Lukacs et al., 
2013; Senning et al., 2014). 
TRPV1 was initially identified in small-diameter 
sensory neurons of dorsal root ganglia (Caterina et al., 
1997) and subsequent studies shown that TRPV1 is also 
expressed in the cell bodies of small to medium sized 
primary afferents, located in dorsal root, trigeminal dorsal 
horn, nodose ganglia and in the brainstem nucleus tractus 
solitaries (Roberts and Connor, 2006). Moreover, 
different investigations cloned and characterised TRPV1 
orthologues in the majority of mammalian and birds 
tissues (Hayes et al., 2000; Jordt and Julius, 2002; 
Savidge et al., 2002; Correll et al., 2004; Gavva et al., 
2004; Phelps et al., 2005). 
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TRPV1 and Pain 
TRPV1 activation in the primary afferent neurons 
results in the release of pro-inflammatory peptides and 
action potential-dependent with a release of glutamate 
from the peripheral nervous system and to a central 
widespread of neuropeptides, to amplify this signal and 
increase the sensitivity of the dorsal horn neurons to other 
incoming signals from the periphery (Roberts and 
Connor, 2006; Morales-Lázaro and Rosenbaum, 2014). It 
was demonstrated that TRPV1 has a double role: First, it 
is able to detect the damaging stimuli, perceived as 
painful and after it contributes to the transmission to the 
central nervous system (Roberts and Connor, 2006). 
The perception of pain is not easily definable because 
it can vary for each species and subjects. Considering 
human beings, the definition of pain (as defined by the 
International Association for the Study of Pain-IASP-) is 
a physiological response to a noxious stimulus that causes 
an unpleasant feeling, decreasing the quality of life of 
those affected by it. Moreover, it should be borne in 
mind, that TRPV1 can be sensitized, leading to an 
increase in its response to a given stimulus or desensitized 
rendering it refractory to activation and could vary its 
expression (down-regulation or up-regulation) during 
tissue injury, inflammation and bone cancer (Ueda, 2006; 
Premkumar and Bishnoi, 2011; Pan et al., 2010). 
This is why TRPV1 has become a promising target for 
pain-relieving therapies. 
A persistent pain state could lead to hyperalgesia, 
which is defined as an increased and exaggerated 
responsiveness to a noxious stimulus. This can be due to a 
greater sensitization of the peripheral endings of nerve 
fibres or to alterations in TRPV1 gene/protein. In humans, 
it was demonstrated that hyperalgesia can occur in cancer, 
infection, post-operative pain and neuropathies associated 
with diabetes and Human Immunodeficiency Virus (HIV). 
Another aspect of neuropathic pain is allodynia, in which is 
pain is evoked by a normally innocuous stimulus and 
probably it is the last step of TRPV1 alteration in 
nociception (Roberts and Connor, 2006). 
Many animal models were and are used to study 
TRPV1 in pain perception, transmission and alteration 
(hyperalgesia and allodynia), with the main goal to find 
an efficient treatment (Kuffler et al., 2002; Chen et al., 
2009; Malek et al., 2012).  
Frogs 
TRPV1 was identified in frogs and its involvement 
was investigated in pain perception after a heat noxious 
stimulation (Ohkita et al., 2012). Noxious heat was 
applied to frog Dorsal Root Ganglion (DRG) neurons and 
consequently they produced a membrane current with 
similar properties to mammalian primary sensory 
neurons. Anyway this current was not influenced by 
capsaicin and its antagonists. A previous study shown that 
acids were able to induce a slow current membrane 
inactivation that was selectively carried by Na
+ 
and 
inhibited by noxious heat (Kuffler et al., 2002). Taking 
into consideration the results of both studies, it is possible 
to suppose that the TRPV1 reaction to noxious heat in 
frogs is different from that in mammals: TRPV1 plays the 
role of polymodal detector for noxious stimuli in 
mammals while in frogs these functions could be 
managed by distinct ion channels. 
Mice 
Mice were largely use to investigate TRPV1 in 
transducing thermal and inflammatory pain. Mice lacking 
the TRPV1 gene demonstrate deficits in thermal or 
inflammation pain, but maintain part of sensitivity to 
noxious heat (Premkumar et al., 2002). Moreover, 
TRPV1 deficient mice do not display thermal 
hypersensitivity following tissue injury (Caterina et al., 
2000; Davis et al., 2000), substantiating the hypothesis 
that capsaicin receptor is a polymodal integrator of 
noxious chemical and physical stimuli in vivo (Jordt and 
Julius, 2002; Rehman et al., 2013). The murine model 
was also used in the recent past to study the modulation 
of TRPV1 activation via Phorbol 12-Myristate 13-Acetate 
(PMA) inducing Protein Kinase C (PKC) 
phosphorylation. Some studies suggested that PMA can 
induce phosphorylation of PKC modulating TRPV1 
activation and leading to a decrease of the heat threshold 
of TRPV1 activation from 42°C to 32°C that means that 
TRPV1 could also be activated at physiological 
temperatures and PKC-mediated phosphorylation should 
be sufficient to activate TRPV1 (Correll et al., 2004). 
Others suggested that PMA-induced activation of PKC 
could only minimally activate TRPV1 (Crandall et al., 
2002; Vellani et al., 2001) compared to capsaicin-
evoked activation. The study of Correll et al. (2004) was 
in contrast with the previous one and found that PMA 
induced activation of TRPV1 is highly efficacious at the 
physiological temperature of 37°C and they were able to 
monitored and assessed the full induction of TRPV1 by 
a PKC-mediated pathway. 
Rats 
Rat is another widely used animal model to investigate 
how TRPV1 can act in nociception. This receptor was 
identified in trigeminal ganglion in a study concerning the 
role of TRPV1 in orthodontic pain responses: Results 
revealed that TRPV1 expression is modulated by 
experimental tooth movement and it is actively involved 
in tooth-movement pain (Qiao et al., 2014). 
The paper of Gui et al. (2013) investigated the role of 
TRPV1 in bone pain following metastatic spread of breast 
cancer cells. TRPV1 positive neurons were more 
expressed in cancer-bearing rats, but substance P (a 
neuropeptide involved in nociception) release has no 
difference, suggesting that TRPV1 responsive neurons 
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were activated in the model. Moreover, TRPV1 was 
identified in innervating femur in rat under physiological 
conditions and during osteoporosis experimental model 
where it is possible to appreciate an increaseof TRPV1 
expression (Yoshino et al., 2014). 
The study of Yamamoto et al. (2007) identified and 
characterized TRPV1 in intraepithelial and subepitelial 
nerve ending in airway smooth muscle cells and tracheal 
mucosa in rats. They investigate also TRPV2 that was 
mainly observed in nerve fibres of the tracheal sub 
mucosal layer and in intrinsic ganglion cells in the 
peritracheal plexus (Yamamoto et al., 2007). TRPV1-
immunoreactive nerve fibres were also positive for 
substance P or Calcitonin Gene-Related Peptide (CGRP-a 
peptide involved in transmission of pain sensation in both 
central and peripheral nervous system neurons), but 
neither neuropeptides were co-localized with TRPV2: 
These results suggested the possible involvement of 
TRPV1 in thacheal nociception, but the different 
expression ofTRPV1, TRPV2 and neuropeptides may 
reflect the presence of subpopulation of sensory neurons 
(Yamamoto et al., 2007). A recent study investigated the 
expression and the functionality of TRPV1 channel in 
Airway Smooth Muscle Cells (ASMCs) proliferation: 
This process is the basis of airway remodelling that can 
lead to severe asthma and the results of this study 
demonstrated that specific agonists and antagonists could 
modulate cell proliferation (Zhao et al., 2014). 
Avians 
In avian species, it was identified the cVR1 (chicken 
analog of TRPV1), that has functional properties similar to 
mammalian TRPV1 but shows residual sensitivity to 
vanilloid compounds, as evidenced at high capsaicin 
concentrations (Jordt and Julius, 2002). Differences between 
avian and mammalian TRPV1 orthologues could explain 
why mammalian predators are repelled by pepper plants, 
whereas birds are favoured as vectors for seed dispersal 
(Tewksbury et al., 1999; Tewksbury and Nabhan, 2001). 
Dogs 
The first identification of TRPV1 in dog Tissues 
(dTRPV1) was done by Phelps et al. (2005): The receptor 
displayed similarities to human’s orthologue suggesting 
that dog could be a good model for inflammatory diseases 
and nociception. Nowadays, canine experimental model 
concerning TRPV1 is commonly used in oncologic 
researches (Pihno et al., 2012; Vercelli et al., 2013). 
Therapeutic Strategies using TRPV1 Agonists and 
Antagonists 
Recent studies tried new pharmacological treatments 
specifically targeted to TRPV1 receptorfor the control of 
pain and inflammatory conditions in a variety of diseases 
and injury states, considering the development of several 
TRPV1 agonists and antagonists. 
Clinical trials were performed on healthy or suffering 
of chronic pain volunteers: Local application of capsaicin 
(as 0.025%-0.075% cream preparations) resulted better 
than placebo at reducing pain associated with post-
herpetic neuralgia, diabetic neuropathy, osteoarthritis and 
musculoskeletal disorders (Roberts and Connor, 2006; 
Chong et al., 2007; Kwak, 2012). Anyway it is important 
to underlie that the local application leads to a burning 
sensation and erythema, but few serious side effects 
(Spruce et al., 2003; Galluzzi et al., 2007; Brito et al., 
2014). Capsaicin application also produces a release of 
substance P and CGRP in the skin and it is possible that 
continued application of capsaicin depletes peripheral 
terminals of these pro-nociceptive substances (Kwak, 
2012). Finally, continuous or repetitive capsaicin 
application leads to a blunting of many cutaneous sensory 
modalities and this is associated with a reversible loss of 
epidermal nerve fibres coinciding with the onset of the 
sensory deficits (Kwak, 2012). High-dose capsaicin, 
when tolerated, has the potential for long-term analgesia 
in certain types of neuropathic pain (Smith and Brooks, 
2014) and recently it was reviewed that TRPV1 is also 
involved in synaptic plasticity with functional implications 
of TRPV1 in CNS, partly due to its multimodal form of 
activation and highlighting the potential pharmacological 
implications of TRPV1 in the brain (De Petrocellis and 
Moriello, 2013; Edwards, 2014).  
The ultrapotent TRPV1 agonist, Reniferatoxin (RTX) 
is studied because it seems that it can lead to a long term 
TRPV1 desensitisation, lasting for weeks (Choi et al., 
2009). RTX has been used in the treatment of urinary 
incontinence in humans (Bley, 2004) and for cancer bone 
pain (Brown et al., 2005). 
Several TRPV1 antagonists have been studied to 
alleviate or reverse mechanical and thermal hyperalgesia 
associated with inflammatory pain. The main hypothesis 
concerning their mechanism of action is that antagonists 
could block TRPV1 activation through interfering with 
conformational changes required for channel activation at 
distinct sites from those for protons or capsaicin actions, 
such as the putative camphor activation site (Roberts and 
Connor, 2006; Morales-Lázaro and Rosembaum, 2014). 
The first reported TRPV1 antagonist, capsazepine, was 
discovered by modifying the chemical backbone of 
capsaicin (Walpole et al., 1994). Capsazepine competes 
for the capsaicin-binding site on TRPV1, blocks 
capsaicin-induced channel activation in neonatal rat 
dorsal root ganglion (Brito et al., 2014).  
Some study tried to use TRPV1 antagonists in the 
reduction of mechanical hyperalgesia and in models of 
inflammatory and post-operative pain with positive 
effects, but the mechanism of action is not yet perfectly 
clear. Capsazepine was found to be extremely useful in 
laboratory research, leading to the hypothesis that it could 
be considered an important candidate for clinical use. 
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Unfortunately, clinical trials belied this chance. One of 
the reasons is that capsazepine has a low metabolic 
stability and poor pharmacokinetic properties as 
demonstrated in rodents (Vriens et al., 2009). Moreover, it 
is apparently non-selective (Broad et al., 2008; Pal et al., 
2009; Wong et al., 2009) and appearing or cross-reactive: 
While inhibiting TRPV1, capsazepine also inhibited 
nicotinic acetylcholine receptors voltage-gated Ca
2+
 
channels and TRPM8 (Liu et al., 1997; Weil et al., 2005). 
Capsazepine illustrated species-dependent effects in 
various models of chronic inflammatory and neuropathic 
pain possibly due to the species-related differences in the 
binding of capsazepine to TRPV1: Anti-hyperalgesic effect 
of capsazepine was more effective in reversing the 
persistent inflammatory and neuropathic pain in guinea 
pig than in mice or rats (Walker et al., 2003).  
The 5-Iodo-Renifertoxin (5-I-RTX) was administered 
in systemically to attenuate bone cancer related pain 
(Ghilardi et al., 2005). 
It is necessary to remark that the systemic use of 
TRPV1 antagonist should be carefully considered 
because, it must be borne in mind that TRPV1 channel is 
expressed also in physiological conditions and that it was 
demonstrated that a systemic TRPV1 block can occur 
(Premkumar and Sikand, 2008). 
Conclusion 
Since its cloning over a decade ago, research on 
TRPV1 has grown considerably and nowadays TRPV1 is 
one of the most studies TRP receptors. The increasing 
interest on TRPV1 is not only the role of this channel in 
mediating inflammatory and chronic pain (Re et al., 2007), 
but also is involvement in a huge number of pathologies 
(especially oncology) and diseases ranging from diabetes 
and urinary incontinence to arthritis and hearing loss (Bley, 
2004; Brito et al., 2014). However, although the 
compounds used in clinical trials, the therapeutic utility of 
TRPV1 agonist and antagonists is yet to be validated 
unequivocally, both for humans and animals. 
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